References
- Harvei S., Solheim Ø. The prognosis in osteosarcoma: Norwegian national data. Cancer 1981; 48: 1719–23
- Saeter G., Alvegård T. A., Elomaa I., Stenwig A. E., Holmstró Um T., Solheimör P. Treatment of osteosarcoma of the extremities with the T-10 protocol with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate. A Scandinavian Sarcoma Group study. J Clin Oncol 1991; 9: 1766–75
- Meyers P. A., Heller G., Healey J. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Ket-tering experience. J Clin Oncol 1992; 10: 5–15
- Winkler K., Bieling P., Bielack S. Local control and survival from the Cooperative Osteosarcoma Study Group studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin Orthop 1991; 270: 79–86
- Bacci G., Picci P., Ferrari S. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities: Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72: 3227–38
- Bertoni F., Dallera P., Bacchini P., Marchetti C., Campobassi A. The Istituto Rizzoli-Beretta experience with osteosarcoma of the jaw. Cancer 1991; 68: 1555–63
- Shin K-H, Rougraff B. T., Simon M. A. Oncologic outcomes of primary bone sarcomas of the pelvis. Clin Orthop 1994; 304: 207–17
- Rosen G., Caparros B., Huvos A. G. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982; 49: 1221–30
- Fahey M., Spanier S. S., Vander Griend R. A. Osteosarcoma of the pelvis. A clinical and histopathological study of twenty-five patients. J Bone Joint Surg Am 1992; 74: 321–30
- Saeter G., H0ie J, Stenwig A. E., Johansson A. K., Hannisdal E., Solheim ØP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995; 75: 1084–93
- Smeele L. E., Van der Wal J. E., Van Diest P. J., Van der Waal I., Snow G. B. Radical surgical treatment in craniofacial osteosarcoma gives excellent survival. A retrospective cohort study of 14 patients. Eur J Cancer [B] 1994; 30B: 374–6
- Bruland ØS, Pihl A. Immunoscintigraphy and radioimmunotherapy. Useful approaches in the management of osteogenic sarcoma?, J. Novak. Frontiers of osteosarcoma research. Hogrefe and Huber. 1993; 59–149
- Bruland Øs, Aas M., Solheim Øp, Winderen M., Høie J. Treatment of metastatic disease in osteosarcoma patients. New applications of radiolabeled poly- and bisphospho-nates. Bone and Mineral 1994; 25: 78
- Winkler K., Beron G., Kotz R. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/ Austrian study. J Clin Oncol 1984; 2: 617–24
- Strander H., Bauer H. C., Brosjo O. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995; 34: 877–80
- Kleinerman E. S., Meyers P. A., Raymond A. K., Gano J. B., Jia S-F, Jaffe N. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: Tolerability, toxicity, and immune stimulation. J Immunother 1995; 17: 181–93